P. Gallant

发表

Classification of kinase inhibitors using a Bayesian model.

Xiaoyang Xia, E. Maliski, P. Gallant, 2004, Journal of medicinal chemistry.

A quantitative analysis of kinase inhibitor selectivity

Mindy I. Davis, L. Wodicka, P. Zarrinkar, 2008, Nature Biotechnology.

Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.

Daniel Elbaum, P. Gallant, A. Coxon, 2007, Journal of medicinal chemistry.

Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.

David P. Carney, P. Gallant, M. Morrison, 2011, Bioorganic & medicinal chemistry letters.

Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.

P. Gallant, T. Bush, M. Morrison, 2010, Journal of medicinal chemistry.

Discovery of a potent and selective series of pyrazole bacterial methionyl-tRNA synthetase inhibitors.

P. Gallant, Elsa Mak, J. Finn, 2003, Bioorganic & medicinal chemistry letters.

Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.

P. Gallant, A. Oliveira-dos-Santos, J. Newcomb, 2008, Journal of medicinal chemistry.

Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.

P. Gallant, A. Oliveira-dos-Santos, J. Newcomb, 2008, Journal of medicinal chemistry.

Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.

Xin Huang, David Powers, Daniela Metz, 2006, Journal of medicinal chemistry.

A series of quinoline analogues as potent inhibitors of C. albicans prolyl tRNA synthetase.

P. Gallant, J. Finn, J. Silverman, 2001, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationships of a series of novel thiazoles as inhibitors of aminoacyl-tRNA synthetases.

P. Gallant, P. Wendler, A. Kluge, 1999, Bioorganic & medicinal chemistry letters.

Viscosities and Molar Volumes of Some Specially Selected Liquid Mixtures at 298.15 K

P. Gallant, V. Fried, W. Hirsch, 1988 .

N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.

P. Gallant, A. Cheng, J. Newcomb, 2008, Bioorganic & medicinal chemistry letters.

Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors.

P. Gallant, M. Morrison, P. Rose, 2007, Bioorganic & medicinal chemistry letters.

Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.

Richard Kendall, P. Gallant, M. Morrison, 2007, Journal of medicinal chemistry.

The identification of quality antibacterial drug discovery targets: a case study with aminoacyl-tRNA synthetases

John Finn, P. Gallant, P. Wendler, 2000 .

Detection of small-molecule enzyme inhibitors with peptides isolated from phage-displayed combinatorial peptide libraries.

P. Gallant, D. Fowlkes, J. Zhang, 2000, Chemistry & biology.

Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.

P. Gallant, M. Morrison, D. Elbaum, 2006, Journal of medicinal chemistry.

Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase.

David Powers, Paul Hughes, Richard Kendall, 2007, Journal of medicinal chemistry.

Safegel 1 Day, une lentille à libération de hyaluronate de sodium

P. Gallant, H. Meunier, C. Peyre, 2008 .